An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

Phase 3TerminatedNCT02503176

Kissei Pharmaceutical Co., Ltd.

Overview

The purpose of this study is to evaluate of the long-term safety and efficacy of KCT-0809 in dry eye patients with Sjögren's syndrome.

Study Type

INTERVENTIONAL

Conditions

Dry Eye With Sjögren's Syndrome

Interventions

KCT-0809 ophthalmic solutionDRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Dry eye patients with Sjögren's syndrome finished KCT1301 study Exclusion Criteria: * Patients with poor adherence to medication of study drug in KCT1301 study

Locations (1)

Unnamed facility

Multiple Locations, Japan

Outcomes

Primary Outcomes

Incidences of adverse events

Time frame: 52 weeks

Secondary Outcomes

Score of the corneal staining

Time frame: 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.